Literature DB >> 3032098

Inhibition of DNA gyrase by optically active ofloxacin.

M Imamura, S Shibamura, I Hayakawa, Y Osada.   

Abstract

Inhibition of DNA gyrase activity by optically active ofloxacins was studied and compared with the inhibition of norfloxacin and ciprofloxacin. The (-)-isomer of ofloxacin inhibited the supercoiling activity of gyrase from Micrococcus luteus more effectively than did the (+)-isomer. The 50% inhibitory concentrations of (-)-, (+/-)-, and (+)-ofloxacin; norfloxacin; and ciprofloxacin for gyrase from Escherichia coli were 0.78, 0.98, 7.24, 0.78, and 1.15 microgram/ml, respectively. These values correlated well with the antibacterial activity of each compound against intact bacterial cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032098      PMCID: PMC174716          DOI: 10.1128/AAC.31.2.325

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  DNA gyrase: purification and catalytic properties of a fragment of gyrase B protein.

Authors:  M Gellert; L M Fisher; M H O'Dea
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

2.  Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme.

Authors:  A Sugino; C L Peebles; K N Kreuzer; N R Cozzarelli
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

3.  DNA gyrase: an enzyme that introduces superhelical turns into DNA.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; H A Nash
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

4.  Replication of colicin E1 plasmid DNA in cell extracts.

Authors:  Y Sakakibara; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1974-03       Impact factor: 11.205

5.  Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA.

Authors:  L L Shen; A G Pernet
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

6.  Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli.

Authors:  D C Hooper; J S Wolfson; K S Souza; C Tung; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

7.  Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids.

Authors:  M M Zweerink; A Edison
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

8.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

9.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

10.  Synthesis and antibacterial activities of optically active ofloxacin.

Authors:  I Hayakawa; S Atarashi; S Yokohama; M Imamura; K Sakano; M Furukawa
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

View more
  24 in total

1.  Selective biotransformations. Patents and literature.

Authors:  J S Dordick
Journal:  Appl Biochem Biotechnol       Date:  1989-12       Impact factor: 2.926

2.  Antagonism of wild-type and resistant Escherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers.

Authors:  J S Wolfson; D C Hooper; E Y Ng; K S Souza; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

3.  In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.

Authors:  D Gargallo-Viola; M Esteve; S Llovera; X Roca; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of inhaled antimicrobials.

Authors:  Chris Stockmann; Jessica K Roberts; Venkata K Yellepeddi; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

5.  In vitro activity of DR-3355, an optically active ofloxacin.

Authors:  T Une; T Fujimoto; K Sato; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.

Authors:  S L Kang; M J Rybak; B J McGrath; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

7.  Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and with ofloxacin.

Authors:  M G Cormican; R N Jones
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

8.  Mechanism of differential activities of ofloxacin enantiomers.

Authors:  I Morrissey; K Hoshino; K Sato; A Yoshida; I Hayakawa; M G Bures; L L Shen
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis.

Authors:  N Nakanishi; S Yoshida; H Wakebe; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

10.  Inhibition by quinolones of DNA gyrase from Staphylococcus aureus.

Authors:  M Tanaka; K Sato; Y Kimura; I Hayakawa; Y Osada; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.